iShares Genomics Immunology and Healthcare ETF (ARCA: IDNA)

에 대한 최신 뉴스 iShares Genomics Immunology and Healthcare ETF (ARCA:IDNA)

Healthcare

Basic Materials

Other

The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 10% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.

Roche Holding A.G.

Gilead Sciences Inc

Sarepta Therapeutics Inc

Revolution Medicines Inc Ser C Pc Pp

Incyte Corp.

Regeneron Pharmaceuticals, Inc.

Exelixis Inc

Takeda Pharmaceutical Co Ltd

Sanofi SA

Beigene, Ltd.

Springworks Therapeutics Inc

GSK plc

Genmab A.S.

Merck & Co. Inc.

iShares Genomics Immunology and Healthcare ETF

Geneva,,Switzerland,,June,15,,2023:,Who,World,Health,Organization,Headquarters

Equities

News

Health Care

Markets

IDNA

MRNA

NVAX

미국 질병통제예방센터(CDC)가 세계보건기구(WHO)와의 협력을 중단한 것으로 알려지면서 전 세계 보건 우려가 월요일 높아지는 가운데, 캘리포니아에서 희귀한 H5N9 조류 독감 변종이 발견되어 백신 회의론자 로버트 F. 케네디 주니어에 대한 상원 인준 청문회가 예정된 것과 동시에 이루어졌다.

CDC-WHO 협력 중단 및 조류 독감으로 모더나, 화이자 상승; RFK Jr. 후보 인준 청문회 예정

Idena

Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Overweight and raises the price target from $90 to $105.

Price Target

Reiteration

Analyst Ratings

TMDX

Piper Sandler Reiterates Overweight on TransMedics Group, Raises Price Target to $105

UBS analyst Timothy Arcuri maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and lowers the price target from $215 to $165.

UBS Maintains Buy on ARM Holdings, Lowers Price Target to $165

Piper Sandler analyst Matthew Clark maintains Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) with a Overweight and lowers the price target from $108 to $96.

PFBC

Piper Sandler Maintains Overweight on Preferred Bank, Lowers Price Target to $96

Buybacks

Wells Fargo Board Authorizes $40B Stock Repurchase Program

<a href="https://x.com/JStein_WaPo/status/1917220665821634689" title="https://x.com/JStein_WaPo/status/1917220665821634689">https://x.com/JStein_WaPo/status/1917220665821634689</a>

AMZN

Washington Post Reporter, Jeff Stein, On X Posts "Amazon Spox now saying this was never under consideration for the main Amazon website. Says Amazon Haul has considered listing import price duties on certain products"

UBS analyst Timothy Arcuri maintains Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy and lowers the price target from $30 to $22.

ALGM

UBS Maintains Buy on Allegro Microsystems, Lowers Price Target to $22

Stephens &amp; Co. analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Neutral and lowers the price target from $77 to $47.

Downgrades

SWTX

Stephens & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47

UBS analyst Matheus Enfeldt maintains Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) with a Neutral and lowers the price target from $10.5 to $9.9.

AGRO

UBS Maintains Neutral on Adecoagro, Lowers Price Target to $9.9

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Tuesday.
Shares of Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) rose sharply during Tuesday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/HON/earnings">raised its FY25 adjusted EPS guidance</a>.
Revenue grew 8% year-over-year (Y/Y, organic: +4% Y/Y) to $9.82 billion, beating the consensus of $9.59 billion. Adjusted EPS was $2.51 (+7% Y/Y), beating the consensus of $2.21.
Honeywell International shares climbed 4.9% to $210.54 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares jumped 23% to $34.99 after the company announced a collaboration with Novo Nordisk to offer a bundled package of all dose strengths of Wegovy on its platform.</li>
<li>Leggett &amp; Platt, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) gained 21.1% to $8.81 after the company reported better-than-expected first-quarter EPS results and raised its FY25 EPS guidance.</li>
<li>Clarivate Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>) jumped 16.8% to $4.1950 after the company reported better-than-expected quarterly financial results.</li>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) jumped 16% to $24.90 as the company raised its FY2025 sales guidance.</li>
<li>CECO Environmental Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) gained 15.7% to $22.22 following upbeat quarterly earnings.</li>
<li>LZ Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) rose 14.8% to $9.19.</li>
<li>ProPetro Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUMP#NYSE">PUMP</a>) shares rose 11.2% to $5.86 after the company reported a first-quarter adjusted EPS and revenue beat.</li>
<li>TriMas Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRS#NYSE">TRS</a>) gained 11.2% to $23.34 following better-than-expected quarterly earnings.</li>
<li>Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) gained 10.4% to $87.96 after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>Metsera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) rose 10.2% to $21.83.</li>
<li>EPWK Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>) rose 9.4% to $15.00.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) gained 7% to $96.04 after the company reported better-than-expected quarterly financial results and raised its FY25 adjusted EPS guidance.</li>
<li>Noble Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) rose 6.4% to $22.36 after the company reported better-than-expected quarterly sales results.</li>
<li>Crane Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) gained 5.3% to $156.47 following upbeat quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Earnings

Intraday Update

Movers

CECO

CLVT

EPWK

FOUR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KNSA

LZMH

MTSR

PUMP

Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday

Piper Sandler analyst Frank Schiraldi maintains Meridian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRBK#NASDAQ">MRBK</a>) with a Neutral and lowers the price target from $17 to $16.

MRBK

Piper Sandler Maintains Neutral on Meridian, Lowers Price Target to $16

UBS analyst Gavin Parsons maintains Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Buy and raises the price target from $200 to $220.

UBS Maintains Buy on Woodward, Raises Price Target to $220

DAAQU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Piper Sandler analyst Nathan Race maintains First Savings Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSFG#NASDAQ">FSFG</a>) with a Overweight and raises the price target from $30 to $32.

FSFG

Piper Sandler Maintains Overweight on First Savings Financial, Raises Price Target to $32

UBS analyst Kevin Caliendo maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Buy and raises the price target from $708 to $805.

UBS Maintains Buy on McKesson, Raises Price Target to $805

Piper Sandler analyst Nathan Race maintains First Northwest Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNWB#NASDAQ">FNWB</a>) with a Neutral and raises the price target from $11.5 to $12.

FNWB

Piper Sandler Maintains Neutral on First Northwest Bancorp, Raises Price Target to $12

UBS analyst Kunal Madhukar maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Neutral and raises the price target from $72 to $73.

EBAY

UBS Maintains Neutral on eBay, Raises Price Target to $73

UBS analyst Kevin Caliendo maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Buy and raises the price target from $298 to $335.

UBS Maintains Buy on Cencora, Raises Price Target to $335

Piper Sandler analyst Luke Lemoine maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Neutral and lowers the price target from $46 to $44.

Piper Sandler Maintains Neutral on Schlumberger, Lowers Price Target to $44

Macro Economic Events

Econ #s

Economics

Dallas Fed Texas Service Sector Index Of General Business Activity Outlook -19.4 In April Vs -11.3 In March

Dallas Fed Texas Service Sector Revenue Index 3.8 In April Vs 1.3 In March

미국 질병통제예방센터(CDC)가 세계보건기구(WHO)와의 협력을 중단한 것으로 알려지면서 전 세계 보건 우려가 월요일 높아지는 가운데, 캘리포니아에서 희귀한 H5N9 조류 독감 변종이 발견되어 백신 회의론자 로버트 F. 케네디 주니어에 대한 상원 인준 청문회가 예정된 것과 동시에 이루어졌다.
무슨 일이 있었나: 이러한 사태는 의료 관련 주식에 파장을 일으켰고, 백신 제조사들은 혼재된 반응을 보였다. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)는 월요일 0.58% 상승했고, 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)는 조류 인플루엔자 대비 준비 가능성에 대한 관심이 높아지면서 2.95% 상승했다.
CDC의 존 응켄가송(John Nkengasong) 공식의 일요일 메모는 <a href="https://apnews.com/article/cdc-who-trump-548cf18b1c409c7d22e17311ccdfe1f6">AP 통신</a>에 보도된 바와 같이 WHO와의 모든 협력을 즉시 중단하라는 명령을 내렸으며, 이는 미국이 올해 13건의 홍역 발병을 포함한 여러 건강 문제에 직면한 상황에서 건강 전문가들을 놀라게 했다.
첫 번째 H5N9 발생은 머시드 카운티의 한 오리 농장에서 발견되었으며, 더 일반적인 H5N1 바이러스와 함께 발견되어 119,000마리의 조류가 도살되었다고 로이터가 보도했다.
이 발견은 전국적으로 계란 가격이 12개에 4.15달러로 치솟은 12월에 발생했다. 미국 농무부는 조류 인플루엔자 영향으로 올해 계란 가격이 추가로 20% 상승할 것으로 전망하고 있다고 별도의 AP 통신 <a href="https://apnews.com/article/egg-prices-bird-flu-poultry-inflation-9ea9934e20e3fe393abb1bb85aa31c30">보도</a>했다.
타이밍은 특히 중요하다. 백신 회의론자로 알려진 케네디는 이번 주 보건복지부 장관 인준 청문회를 앞두고 있다. 그의 잠재적 임명은 이미 시장 심리에 영향을 미쳤으며, 일부 백신 주식은 변동성을 보였다.
&#8220;동시에 WHO와의 분리와 새로운 건강 위협이 발생하는 것은 의료 투자자들에게 상당한 불확실성을 야기한다&#8221;고 제프리 클라우스너(Jeffrey Klausner) 박사, 남가주대학교 공공보건 전문가가 말했다.
참고: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%EB%94%A5%EC%8B%9C%ED%81%AC%EA%B0%80-%EC%88%98%EC%B6%9C-%ED%86%B5%EC%A0%9C%EB%A5%BC-%EC%A4%80%EC%88%98%ED%95%98%EB%A9%B4%EC%84%9C-%EC%83%88-ai-%EB%AA%A8%EB%8D%B8/" target="_blank" rel="noopener">엔비디아가 딥시크를 &#8216;사례&#8217;로 언급하며 새로운 AI 모델이 수출 통제 준수 하에 생성될 수 있음을 설명</a>
중요한 이유: 의료 부문의 반응은 더 넓은 시장 우려를 반영한다. iShares Genomics Immunology and Healthcare ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NASDAQ">IDNA</a>)는 올해 1.2% 상승한 반면, <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">주요 백신 생산자들</a>는 여전히 독감 대비를 위해 정부 계약을 상당수 보유하고 있다.
사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), 글락소스미스클라인 PLC(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) 그리고 다른 제조사들은 작년 10월 조류 인플루엔자 백신 생산을 위한 7,200만 달러의 연방 자금을 확보했다. 모더나는 mRNA 기반 H5N1 백신 개발을 위해 미국 보건부(HHS) 산하 질병예방대응본부(ASPR) 직속 생물의학첨단연구개발국(BARDA)로부터 1억 7,600만 달러를 별도로 받았다.
CDC의 결정은 도널드 트럼프 대통령의 WHO 탈퇴 명령에 따른 것이지만, 완전한 탈퇴는 의회의 <a href="https://www.benzinga.com/25/01/43125408/trump-signs-order-to-withdraw-us-from-who-again-cites-funding-governance-concerns">승인과 1년의 통지 기간</a>이 필요하다.

다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/crypto/bitcoin/%EB%B9%84%ED%8A%B8%EC%BD%94%EC%9D%B8-%EC%9D%B4%EB%8D%94%EB%A6%AC%EC%9B%80-%EB%B0%8F-%EB%8F%84%EC%A7%80%EC%BD%94%EC%9D%B8%EC%9D%B4-%EC%86%8C%ED%8F%AD-%ED%9A%8C%EB%B3%B5-%EB%94%A5%EC%8B%9C%ED%81%AC/" target="_blank" rel="noopener">비트코인, 이더리움, 도지코인, 딥시크 문제로 미국 기술주가 어려움을 겪는 동안 회복: 분석가는 BTC가 향후 2주 동안 새로운 최고가를 기록할 수 있다고 제안</a></li>
</ul>
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 AI 도구의 도움을 받아 부분적으로 작성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

iShares Genomics Immunology and Healthcare ETF

뉴스

에 대한 최신 뉴스 iShares Genomics Immunology and Healthcare ETF (ARCA:IDNA)

화요일, 1월 28, 2025

뉴스

파트너 / 기고자

벤징가 글로벌